FIU researchers develop new pathway to brain for medicine

by Daniel Chang, The Miami Herald

Stumped for years by a natural filter in the body that allows few substances, including life-saving drugs, to enter the brain through the bloodstream, physicians who treat neurological diseases may soon have a new pathway to the organ via a technique developed by a physicist and an immunologist working together at Florida International University's Herbert Wertheim College of Medicine.

The FIU researchers developed the technique to deliver and fully release the anti- AZTTP into the , but their finding has the potential to also help patients who suffer from such as Alzheimer's, Parkinson's and epilepsy, as well as cancer.

"Anything where you have trouble getting drugs to the brain and releasing it, this opens so many opportunities," said Madhavan Nair, an FIU professor and chair of the medical school's immunology department.

In an in-vitro with HIV-infected cells, Nair and a colleague, Sakhrat Khizroev, a professor of immunology and electrical engineering, attached the AZTTP to tiny, magneto-electric nanoparticles. Then, using , they guided the drug across a created in the lab to mimic the blood-brain barrier found in the human body.

Once the drug reached its target, researchers triggered its release from the nanoparticle by zapping it with a low-energy electrical current. The drug remained functional and structurally sound after the release, according to the experiment findings.

"We learned to control electrical forces in the brain using magnetics," said Khizroev, who designed, oversaw and supervised the entire project. "We pretty much opened a pathway to the brain."

The test findings were published in April in the online peer-reviewed journal, Nature Communications. Researchers believe that using this method will allow physicians to send a higher level of AZTTP - up to 97 percent more - to HIV-infected cells in the brain.

Currently, more than 99 percent of the antiretroviral therapies used to treat HIV, such as AZTTP, are deposited in the liver, lungs and other organs before they reach the brain.

While anti-viral drugs have helped HIV patients live longer by reducing their viral loads, the drugs cannot pass the in significant amounts, which allows the virus to lurk unchecked in the brain and can lead to neurological damage, said Dr. Cheryl Holder, a practicing physician and FIU professor who specializes in treating patients with HIV.

"We know that even though the viral load is undetectable in the blood, we don't know what's going on in the brain fully," Holder said.

HIV causes constant inflammation, she said, and the virus can pool in areas of the brain where medicine cannot reach, potentially causing damage.

"It's important to get the drug to the brain," she said, "to help prevent dementia in older patients, and inflammation."

But the ability to target drug delivery and release it on demand in the brain has been impossible without opening the skull, Nair and Khizroev said.

Nair, an who specializes in HIV research, and Khizroev, an electrical engineer and physicist, began collaborating on the project about 18 months ago after winning a National Institutes of Health grant to study the use of magnetic particles.

One of the keys to success was controlling the release of the drug without adversely affecting the brain.

The researchers found their solution in the magneto-electric nanoparticles, which are uniquely suited to deliver and release drugs in the brain, Khizroev said. These nanoparticles can convert magnetic energy into the electrical energy needed to release the drugs without creating heat, which could potentially harm the brain.

The development of a new, less invasive pathway to the brain would open the door to many new medical uses.

Khizroev said he recently returned from a trip to the University of Southern California, where he briefed physicians at the medical school on the technique and its potential for cancer treatment. And Nair said he received a letter recently on behalf of a 91-year-old man suffering from Parkinson's, asking when the technique might become available for use in people.

That may take a while. With the first phase of testing successfully completed using in vitro experiments, the second will take place at Emory University in Georgia, where researchers will test the technique on monkeys infected with the HIV virus.

If researchers complete the second phase successfully, clinical trials on humans could follow, Nair said. Approval from the Food and Drug Administration would be required before the technique becomes commercially available, he said.

FIU researchers have applied for a patent and would receive royalties, they said, though the university would benefit the most, in part because a successful research project could open opportunities for more grant funding on other topics.

For Khizroev, who had previously done research on quantum computing and information processing, the project has offered a way to put his scientific knowledge to use in a way that could have a direct affect on people's health.

"I wanted to apply my knowledge of to something important," he said.

Related Stories

HIV disrupts blood-brain barrier

date Jun 28, 2011

HIV weakens the blood-brain barrier — a network of blood vessels that keeps potentially harmful chemicals and toxins out of the brain — by overtaking a small group of supporting brain cells, according ...

Popular HIV drug may cause memory declines

date Sep 27, 2012

The way the body metabolizes a commonly prescribed anti-retroviral drug that is used long term by patients infected with HIV may contribute to cognitive impairment by damaging nerve cells, a new Johns Hopkins research suggests.

Understanding the link between HIV and dementia

date Jun 29, 2011

(Medical Xpress) -- HIV can hide out in the brain, protected from the immune system and antiviral drugs, Dr. Lachlan Gray and his colleagues at Monash University and the Burnet Institute have found.

Recommended for you

Breathless: How blood-oxygen levels regulate air intake

date 1 hour ago

Researchers have unraveled the elusive process by which small, highly vascular clusters of sensory cells in the carotid arteries "taste the blood," as a 1926 essay put it—the initial step in regulating ...

Sex matters ... even for liver cells

date 2 hours ago

Female liver cells, and in particular those in menopaused women, are more susceptible to adverse effects of drugs than their male counterparts, according to new research carried out by the JRC. It is well ...

Caring for blindness: A new protein in sight?

date 3 hours ago

Vasoproliferative ocular diseases are responsible for sight loss in millions of people in the industrialised countries. Many patients do not currently respond to the treatment offered, which targets a specific ...

When genes are expressed in reverse

date 3 hours ago

Genes usually always be expressed as in Western writing: from left to right on the white canvas of our DNA. So when we speak of the activity of our genome, in fact we are referring to the expression of genes ...

Technique could speed biologic drugs

date 8 hours ago

Antibodies are specific molecules that can lock onto a particular cellular structure to start, stop or otherwise temper a biological process. Because they are so specific, antibodies are at the forefront ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.